Phase III Insulin Add-On Asia Regional Program - ST

NCT02096705 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

477

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes

Interventions

DRUG: Dapagliflozin
DRUG: Dapagliflozin Placebo

Sponsor

AstraZeneca

Collaborators

[object Object]